AWH Capital’s Adicet Bio ACET Stock Holding History

AWH Capital’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-10,625	Closed	-$357K	–	35
2020 Q3	$357K	Buy	10,625 +9,687	+1,033%	+$2.45M	0.5%	36
2020 Q2	$226K	Buy	+938	New	+$184K	0.44%	30

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.82% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

AWH Capital's ACET Position: Q4 2020 in Review

AWH Capital sold out of Adicet Bio (ACET) in Q4 2020, closing a stake of 10,625 shares — an estimated $357K sold.

AWH Capital first reported a position in ACET in Q2 2020 and held it in 2 quarters. The position peaked at $357K in Q3 2020. 44 funds tracked by Wall St. Rank hold ACET as of Q4 2020.

AWH Capital reported no remaining Adicet Bio position as of Q4 2020 after selling out during the quarter.
AWH Capital sold 10,625 Adicet Bio shares in Q4 2020, an estimated $357K.
AWH Capital first reported a position in Adicet Bio in Q2 2020 and held it in 2 quarters.
AWH Capital's Adicet Bio position peaked at $357K in Q3 2020.
44 funds tracked by Wall St. Rank held Adicet Bio as of Q4 2020.

Based on AWH Capital's 13F filing for Q4 2020, filed 16 Feb 2021.